Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials
BPaL and HRZE have similar hepatic safety profiles in their respective populations. Pretomanid and pyrazinamide should be co-administered only when the benefit outweighs the risk.
Authors
- Stephen H. Gillespie (ORCID: https://orcid.org/0000-0001-6537-7712)
- Müge Çevik (ORCID: https://orcid.org/0000-0003-1133-3874)
- Jerry Nedelman (ORCID: https://orcid.org/0000-0002-0205-522X)
- Rebecca S. Bruning (ORCID: https://orcid.org/0000-0003-1229-247X)
- Derek J. Sloan (ORCID: https://orcid.org/0000-0002-7888-5449)
- Maria Beumont
- Jeffrey L. Ambroso (ORCID: https://orcid.org/0000-0001-8730-6034)
- Morounfolu Olugbosi (ORCID: https://orcid.org/0009-0006-2501-868X)
- Min Li (ORCID: https://orcid.org/0000-0002-3578-2239)
- Eugene Sun (ORCID: https://orcid.org/0009-0000-3154-1764)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of St Andrews (GB)
- RTI International (US)
- TB Alliance (US)
Publication Details
- Journal
- IJTLD OPEN
- Published
- 2025-08-01
- DOI
- https://doi.org/10.5588/ijtldopen.25.0199
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00